



Published in final edited form as:

Genet Epidemiol. 2019 October ; 43(7): 844–863. doi:10.1002/gepi.22242.

Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes

A full list of authors and affiliations appears at the end of the article.

Abstract

Epidemiologic studies show an increased risk of non-Hodgkin lymphoma (NHL) in patients with autoimmune disease (AD), due to a combination of shared environmental factors and/or genetic factors, or a causative cascade: chronic inflammation/antigen-stimulation in one disease leads to another. Here we assess shared genetic risk in genome-wide-association-studies (GWAS).

Secondary analysis of GWAS of NHL subtypes (chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma) and ADs (rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis). Shared genetic risk was assessed by (1)description of regional genetic of overlap, (2)polygenic risk score (PRS), (3)“diseasome”, (4)meta-analysis.

Descriptive analysis revealed few shared genetic factors between each AD and each NHL subtype. The PRS of ADs were not increased in NHL patients (nor vice versa). In the diseasome, NHLs shared more genetic etiology with ADs than solid cancers ($p=0.0041$). A meta-analysis (combing AD with NHL) implicated genes of apoptosis and telomere length.

This GWAS-based analysis four NHL subtypes and three ADs revealed few weakly-associated shared loci, explaining little total risk. This suggests common genetic variation, as assessed by GWAS in these sample sizes, may not be the primary explanation for the link between these ADs and NHLs.

Keywords

Autoimmune disease; Non-Hodgkin Lymphoma; Genome-wide Association Study; Meta-Analysis

INTRODUCTION

It is well established that patients with autoimmune diseases (AD) such as rheumatoid arthritis (RA), Sjögren’s syndrome, and systemic lupus erythematosus (SLE) are at increased risk of malignant lymphomas, i.e. Hodgkin and non-Hodgkin lymphomas (NHL). Different mechanisms may plausibly contribute to this association. For instance, an

Corresponding author: Pouya Khankhanian, Pouya.Khankhanian@uphs.upenn.edu, +1 (215) 776-4916, Hospital of University of Pennsylvania, Department of Neurology, 3400 Spruce Street, 3W Gates Bldg (Neurology), Philadelphia, PA 19104.

*These two authors contributed equally to this work: Henrik Hjalgrim, Pouya Khankhanian

DATA AVAILABILITY

Individual cohorts contributing to the meta-analysis should be contacted directly as each cohort has different data access policies. We have included citations for data sources in the reference section.

autoimmune reaction may involve chronic antigenic stimulation and inflammation, which may promote lymphoma development through heightened B- or T-cell activation (Baecklund, Smedby, Sutton, Askling, & Rosenquist, 2014). Increased risks of salivary gland marginal zone lymphomas (MZL) of B-cell origin in patients with Sjögren's syndrome and of small intestinal T-cell lymphomas in patients with celiac disease support such mechanisms (Baecklund, Smedby, Sutton, Askling, & Rosenquist, 2014). AD treatment might also contribute to the observed increased lymphoma risk, for example, through suppression of the immune system (Baecklund, Smedby, Sutton, Askling, & Rosenquist, 2014).

While these mechanisms are intuitively an appealing explanation for the AD-NHL association, the association might also theoretically involve other risk factors shared by the two groups of diseases. In this regard, the current understanding of environmental risk factors possibly shared by ADs and NHLs, such as smoking, offers no convincing explanation for their mutual clustering (Thun, Linet, Cerhan, Haiman, & Schottenfeld, 2017) (Deane, et al., 2010) (Park, et al., 2009) (Belbasis, Bellou, Evangelou, Ioannidis, & Tzoulaki, 2015) (Smedby & Ponzoni, 2017) (Ekström, et al., 2003) (Bernatsky, et al., 2013). Further, meta-analyses of genome-wide association studies (GWAS) suggested genetic overlap between SLE and diffuse large B-cell lymphoma (DLBCL) (Bernatsky, et al., 2017), and between multiple sclerosis (MS) and Hodgkin lymphoma (Khankhanian, et al., 2016) as a partial explanation of the accumulation of those two diseases among relatives.

Here, we use available GWAS data from three ADs, RA, SLE, and MS, and four NHL subtypes, DLBCL, chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and MZL, to explore genetic commonalities between the two disease groups.

MATERIALS AND METHODS

MS, RA, SLE, and NHL Dataset Characteristics

The MS study consists of 9,772 cases and 17,376 controls from the Wellcome Trust Case Control Consortium 2 (WTCCC2) project (International Multiple Sclerosis Genetics Consortium, 2011) (Table 1). Individuals in this dataset were of European descent and originated from 15 geographic regions, including the USA, Australia, New Zealand, and numerous European countries. Included in this dataset were summary-level association results for a total of 464,434 single nucleotide polymorphisms (SNPs). The genotyping platform was the Illumina Human 660-Quad platform; quality control was performed by the original authors and a log-additive genetic model was used.

The RA study consists of a combined 3,921 cases and 4,079 controls of European descent from a meta-analysis of two datasets: Wellcome Trust Case Control Consortium (WTCCC1) (Wellcome Trust Case Control Consortium, 2007) and the Epidemiological Investigation of Rheumatoid Arthritis (EIRA) data set (Padyukov, et al., 2011) (Table 1). The combined dataset (union) had summary-level association results for 650,312 SNPs. The genotyping platform was the Illumina 300K chip; imputation and quality control were performed by the original authors and a log-additive genetic model was used.

The SLE study consists of a combined 7,219 cases and 15,991 controls of European descent from the Bentham et al. multi-center study (Bentham, et al., 2015) (Table 1). The study had summary-level association results for 623,954 SNPs. The genotyping platform was the Illumina HumanOmni1-Quad BeadChip; quality control was performed by the original authors and a log-additive genetic model was used.

The NHL study consists of cases and controls from multiple studies of four B-Cell NHL subtypes: DLBCL (Cerhan, et al., 2014), FL (Skibola, et al., 2014), CLL (Berndt, et al., 2016), and MZL (Vijai, et al., 2015) (Table 1). Individuals in this dataset were also of European descent and originated from the USA and numerous European countries. Together, these datasets include summary-level association results (actual and imputed) for a total of 9,116,853 SNPs for DLBCL, 9,116,853 SNPs for CLL, 9,078,855 SNPs for FL, and 8,478,065 SNPs for MZL.

To generate a single working dataset containing association results for each AD and each subtype of NHL, the datasets were merged according to SNP name, giving a final dataset containing summary-level results for a total of approximately 460,000 overlapping SNPs for MS and each NHL subtype, 600,000 overlapping SNPs for RA and each NHL subtype, and 600,000 SNPs for SLE and each NHL subtype. R and Plink statistical software were used for all subsequent analyses (Purcell, et al., 2007) (R Core Team, 2013)

SNP-level overlap between diseases

For each of the twelve cross-disease analyses, we followed a procedure used in other meta-analyses of complex genetic diseases (Khankhanian, et al., 2016). For example, to assess genetic overlap between MS and DLBCL, we first identified SNPs that associated independently with either disease. Then, in each disease, we grouped SNPs by increasing significance by establishing seven association thresholds ranging from $p < 5 \times 10^{-8}$ to $p < 5 \times 10^{-1}$. From the collection of SNPs that reached a given threshold, we selected only independent subsets ($r^2 < 0.1$ in CEU), preferentially keeping SNPs with lower p-values. (The CEU are controls of Northern and Western European ancestry from CEPH [Centre d'Etude du Polymorphisme Humain] collection based on 1000 Genomes and HapMap genotype data; r^2 was downloaded using SNAP software.) Each subset of SNPs for each AD was tested for association with each NHL subtype. Association test statistics were adjusted for multiple testing using Benjamini-Hochberg's false discovery rate (FDR) method based on the total number of SNPs in the subset. A $FDR < 0.05$ was considered statistically significant. The reverse process was performed to test each set of NHL SNPs and AD risk. SNP-level analyses were conducted for each combination of one autoimmune disease (MS, RA, and SLE) and one subtype of NHL (DLBCL, CLL, FL, and MZL).

Polygenic Risk Scores

Polygenic risk scores (PRS) were calculated to test the cumulative effect of SNPs associated with each AD on NHL and vice versa. For example, for the comparison of SLE and DLBCL, sets of top independent SNPs were chosen as described above. The SLE polygenic risk score (SLE-PRS) and the DLBCL polygenic risk score (DLBCL-PRS) were calculated for each individual; the PRS is defined as the weighted sum of the number of risk alleles at each SNP

in the set, weighted by the log odds ratio of association for each SNP (Khankhanian, et al., 2016). We assessed the ability of the SLE-PRS to distinguish DLBCL cases from controls and the ability of the DLBCL-PRS to distinguish SLE cases from controls using the Nagelkerke R^2 . This analysis was repeated for each combination of one NHL subtype (DLBCL, FL, CLL, and MZL) and one AD (SLE, RA, and MS).

Meta-Analysis

To identify novel susceptibility loci in our merged dataset, we combined summary results from each AD and each NHL subtype in a meta-analysis. For each pair of diseases, for all overlapping SNPs, discovery-level p-values and odds ratios (OR) from the AD and NHL datasets (as provided by the authors of those original studies) were combined using a fixed effects meta-analysis as implemented in the Plink software package. The p-value threshold for Cochran's Q statistic was set to 0.05 to screen for heterogeneity in results across studies.

Diseasome

To visualize the similarities between ADs and the NHL subtypes, we built a human disease network based on disease proximities, as previously described (Khankhanian, et al., 2016) (Daniel Himmelstein; Pouya Khankhanian; Sergio Baranzini, 2015). Briefly, proximity was calculated using a random walk with restart over a heterogeneous network wherein diseases are connected by shared genetic etiology, as determined by databases of previously published data. Two diseases with greater shared genetic etiology will have greater proximity due to a larger number of connections. The mean proximity between NHLs and ADs was compared to the mean proximity between NHLs and solid cancers with the Fisher test. Similarly, the mean proximity between NHL and solid cancers was compared to the mean proximity between NHL and all other diseases (Khankhanian, et al., 2016) (Daniel Himmelstein; Pouya Khankhanian; Sergio Baranzini, 2015)

RESULTS

Overview

A total of 9,772 MS patients, 3,921 RA patients, 7,219 SLE patients, 3,617 DLBCL patients, 2,492 CLL patients, 2,686 FL patients, 741 MZL patients, and 46,436 total controls were analyzed. Figure 1 gives an overview of study design and data analysis. For each of twelve pair-wise comparisons, comparing one of four NHL subtypes against one of three ADs, the following analyses are presented. First, we present SNPs that associated independently with both diseases. Next, we present polygenic risk scores to assess the cumulative genome-wide effect of AD-associated SNPs on NHL and of NHL-associated SNPs on AD. To identify susceptibility genes common to each of twelve disease pairs, a series of twelve GWAS meta-analyses are presented. Finally, the three ADs and the four NHL subtypes from this study were mapped in a genetic diseasome, a network of diseases, with other ADs, NHLs, solid cancers, and other unrelated diseases, and relative proximity of diseases are presented.

SNP and HLA-allele overlap between ADs and NHLs

Each of the three ADs was evaluated for SNP-level overlap with each of the four NHLs, resulting in twelve comparisons. The comparison of SLE versus DLBCL is detailed as an example (Table 2, Row 1). We identified 2,472 SNPs that associated with SLE at a significance threshold of $p < 5 \times 10^{-4}$. After discarding SNPs for which linkage disequilibrium (LD) information was not available, 1,718 SNPs remained representing 389 independent regions (with $r^2 < 0.1$ as the threshold to define independence). Of the 389 SNPs (one SNP per independent region), two of these were significantly associated with DLBCL ($p < 0.05$ after Benjamini-Hochberg correction for 389 multiple tests). Similar results were found when DLBCL-associated SNPs were assessed for association with SLE (Table 2, Row 2). Details regarding the individual overlapping SNPs are given in Supplementary Table 1.

The analysis was repeated for other ADs and other NHL subtypes. In each comparison, a relatively small number of overlapping regions was identified, at most 14. The greatest amount of overlap was observed in the comparisons between MS and CLL and between MS and FL; SLE had a smaller number of overlapping SNPs with the NHL subtypes; and RA had the smallest number of overlapping SNPs with the NHL subtypes. The differences in amount of overlap between specific ADs were small, although it should be noted that this analysis was not equipped to make quantitative assertions about the significance of the difference in overlap (as these differences are highly dependent on other factors including difference in power between studies).

This analysis was repeated with the initial significance thresholds ranging from $p < 5 \times 10^{-8}$ to $p < 5 \times 10^{-1}$; while the results in Table 2 reflect a threshold of $p < 5 \times 10^{-4}$ as an example, a similar pattern of results held at other thresholds. Details of the SNPs comprising this overlap are given in supplementary table 1.

Polygenic risk-overlap between diseases

To assess the extent of genetic risk overlap between AD and NHL subtypes at the genome-wide level (including Human Leukocyte Antigen (HLA) region), polygenic risk scores (PRS), termed MS polygenic risk score (MS-PRS), RA polygenic risk score (RA-PRS), SLE polygenic risk score (SLE-PRS), DLBCL polygenic risk score (DLBCL-PRS), CLL polygenic risk score (CLL-PRS), FL polygenic risk score (FL-PRS), and MZL polygenic risk score (MZL-PRS), were calculated.

In each of the seven individual diseases, the mean PRS was higher in cases than in controls as expected. However, when the PRS of ADs were calculated in NHL subtypes, the score was not significantly different between cases and controls (Supplementary Table 2). Similarly, when PRS of NHL subtypes were calculated in ADs, the scores were not significantly different between cases and controls.

Meta-analysis

We combined each of the three ADs with each of the four NHL GWAS in a series of 12 meta-analyses to leverage increased statistical power for discovery of novel SNPs associated

with both diseases. In Table 3, we report a list of SNPs which had statistically significant association in a meta-analysis of an AD with an NHL subtype, but which did not meet the discovery threshold of significance in the AD alone nor in the NHL subtype alone (though they may not have met the strict definition of genome-wide significance threshold as defined in our study, some of these hits had been carried forward by the original authors to validation on additional samples and subsequently been reported as significant in the original discovery studies). SNPs that passed the analysis paper-wide significance threshold (the “paper-wide threshold” includes correction for total number of tests performed in the total of 12 meta-analyses reported in this paper) are reported in Table 3. SNPs that passed a study-wide significance (after correction only for the total number of SNPs in each meta-analysis) are shown in the supplementary table 3.

Diseasome

We reviewed 87 diseases (Table 4) for which sufficient GWAS results were available in the public domain. Pair-wise proximities between these diseases were calculated based on the degree of genome-wide genetic overlap. A graph of the proximity space reveals a cluster of 19 autoimmune diseases, a cluster of many of the 16 available solid cancers, and a cluster of the four NHLs, which has closer common genetic risk overlap with autoimmune diseases than with solid cancers in this two-dimensional projection (Figure 2, Panel 1). The mean pair-wise proximity metric between NHL subtypes and autoimmune diseases was higher than the mean proximity between NHLs and solid cancers (0.0049 vs. 0.0023, $p = 0.0041$, Figure 2, Panel 2). The mean pair-wise proximity between NHL variants and solid cancers was higher than the mean proximity between NHL and all other diseases (0.0023 vs. 0.0012, $p = 0.00066$, Figure 2, Panel 2).

DISCUSSION

In an effort to understand the association between AD and NHL, we performed a series of analyses exploring genetic overlap between four NHL subtypes and three ADs. We found that only a small number of risk loci associated with NHL were also associated with AD risk, and, conversely, that only a small number of AD risk loci were associated with risk of the NHL subtypes studied. Polygenic risk score analysis, which considers a large number of genes and places less relative weight on the top few genes, did not demonstrate significant genome-wide polygenic overlap between any of the NHL subtypes and any of the AD examined in this study. Diseasome analysis, in contrast to polygenic risk score analysis, places larger relative weight on a fewer number of confirmed top genes. Diseasome analysis revealed that the NHL subtypes tend to occupy a common genetic risk neighborhood and that this common neighborhood is closer to the group of ADs than to the group of solid cancers. Thus, we conclude that while few risk loci overlap between any pair of the studied diseases, there is not enough genetic overlap found in this study to explain an important proportion of increased risk (less than one percent of disease risk explained based on PRS analysis, Supplementary Table 2).

Altogether, within the limitations inherent in the available data our findings provide little evidence that shared genetic risk factors are a major explanation for the increased risk of

malignant B-cell lymphomas in patients with autoimmune diseases such as RA and SLE (Baecklund, Smedby, Sutton, Askling, & Rosenquist, 2014). As this is also the case for known environmental risk factors (Thun, Linet, Cerhan, Haiman, & Schottenfeld, 2017) (Deane, et al., 2010) (Park, et al., 2009) (Belbasis, Bellou, Evangelou, Ioannidis, & Tzoulaki, 2015) (Smedby & Ponzoni, 2017) (Ekström, et al., 2003) (Bernatsky, et al., 2013), other mechanisms, such as inflammation and chronic antigenic stimulation which increase B- and T-cell receptor rearrangement and B-cell somatic hypermutation, and/or AD treatment with immunosuppressive or biologic therapy, seem likely to be more significant contributors to the long-standing association between the two disease groups. The collective findings further suggest that monitoring and managing inflammation or other factors associated with the disease course as the way to reducing the risk of malignant B-cell lymphoma in patients with AD (Baecklund, et al., 2006)

A series of twelve meta-analyses of the three individual ADs with the four individual NHL subtypes demonstrated seven regions which passed a genome-wide threshold of significance in the twelve meta-analyses, which would not have been discovered in analysis of the individual diseases due to limited power (Table 3). The corresponding effect sizes were modest and total risk explained was low, however, the genes in these regions are discussed in a Supplementary Text. In brief, the list comprises genes involved in other cell proliferation and specifically hematopoiesis, telomerase activity, and antigen presentation (via, for example, *MGAT5*). Many of these genes have since been implicated in the ADs and NHLs examined in this manuscript (as larger meta-analyses of the individual ADs and NHLs have been published), which lends credibility to the present findings and supports the potential advantage of the cross-disease meta-analysis approach. Given the availability of studies of the individual ADs and NHLs with larger sample sizes, a repeat meta analysis would be possible.

There are noteworthy limitations of this study. First, this is a *post-hoc* secondary endpoint analysis; validation in an independent dataset would be required to confirm the specific meta-analysis findings, and a series of *in vitro* and *in vivo* studies would be required to elucidate mechanisms and imply causation. Some of the individual NHL subtype GWAS were of relatively small sample size and therefore, the statistical power in these analyses was limited. A lack of whole-exome coverage in a genome-wide study is another limitation; GWAS offer incomplete coverage and an imperfect view of the human genome compared to newer methods. An expansion cross-disease analysis to larger datasets with greater coverage would be of significant value. We completed 12 parallel meta-analyses, which further imposed a limitation on power; the multiple-hypothesis correction for this additional layer of hypothesis testing raised the threshold of genome-wide significance by one order of magnitude and thus limited the power of new discovery. There were many meta-analyses hits that reached genome-wide significance but not paper-wide significance; the vast majority of these were hits that have been confirmed in recent published literature, suggesting that perhaps future meta-analyses should focus on individual disease-pairs, thus avoiding the additional limitation of parallel meta-analysis. The diseaseome analysis was limited by an inability to control for overlap in the control datasets of the individual GWAS used to construct the diseaseome. In particular, for the diseases that were not classified as

NHL or AD, caution against over-interpretation of clusters of diseases with shared GWAS controls is warranted.

The three ADs and the four NHL subtypes presented here were selected because data were available and we were able to create a relationship with the respective consortia. It would be of value for future endeavors to study other auto-immune diseases such as Sjögren's syndrome and other lymphomas such as Hodgkin's lymphoma via a similar analysis pipeline, especially given the observed epidemiologic links between those other syndromes and the ones presented in this study.

CONCLUSION

Within the limits of this GWAS-based cross-disease analysis, we estimated that the shared genetic risk between the three autoimmune diseases and four non-Hodgkin lymphoma subtypes is limited to a handful of genes. This finding suggests that genetic etiology is not the primary driver in the observed epidemiologic link between AD and NHL, but rather the link may be driven by non-genetic factors, such as chronic antigenic stimulation and inflammation or immune-modulating treatment. A meta-analysis of ADs with NHLs suggested new candidate genes to explain the limited shared genetic risk, with roles in the cell cycle, apoptosis, and telomere length. Further meta-analyses of genetic variants in autoimmune diseases and lymphomas with larger datasets and deeper sequencing may provide further insight into mechanisms common to the two groups of diseases.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Authors

Lennox Din,
California Northstate University, Medicine

Mohammad Sheikh,
California Northstate University, Medicine

Nikitha Kosaraju,
Hospital of the University of Pennsylvania, Neurology

Karin E Smedby,
Karolinska Institutet, Karolinska University Hospital, Division of Clinical
Epidemiology, Dept of Medicine

Sasha Bernatsky,
McGill University, Medicine

Research Institute, McGill University Health Centre, Clinical Epidemiology

Sonja Berndt,
National Cancer Institute, Division of Cancer Epidemiology and Genetics

Christine F Skibola,
Emory University, Medicine

Alexandra Nieters,
University Medical Centre Freiburg, Centre of Chronic Immunodeficiency

Sophia Wang,
City of Hope and the Beckman Research Institute, Department of Population
Sciences

James D McKay,
International Agency for Research on Cancer

Pierluigi Cocco,
University of Caligari, Department of Medical Sciences and Public Health

Marc Maynadié,
University of Burgundy-Franche-Comté and CHU Dijon Bourgogne, Registre des
Hémopathies Malignes de Côte d'Or, INSERM U1231

Lenka Foretová,
Masaryk Memorial Cancer Institute, Department of Cancer Epidemiology and
Genetics

Anthony Staines,
Dublin City University, Nursing and Human Science

Thomas M Mack,
University of Southern California, Norris Comprehensive Cancer Center and
Hospital

Silvia de Sanjosé,
Institut Catala d' Oncologia, L'Hospitalet de Llobregat

Timothy J. Vyse,
King's College London, Medical Education

Leonid Padyukov,
Karolinska Institutet, Department of Medicine

Zachary Taub,
University of California, Davis

Morris Din,
California State University Sacramento

Alain Monnereau,
Center of Research in Epidemiology and Statistics, Sorbonne (CRESS),
Epidemiology of childhood and adolescent cancer group, INSERM

Institut Bergonie, Registre des Hémopathies Malignes de la Gironde

Alan A Arslan,
NYU School of Medicine, Obstetrics and Gynecology

Amy Moore,
National Cancer Institute, Division of Cancer Epidemiology and Genetics

Angela R Brooks-Wilson,
Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency
Simon Fraser University, Department of Biomedical Physiology and Kinesiology

Anne J Novak,
Mayo Clinic, Medicine

Bengt Glimelius,
Uppsala Universitet, Department of Immunology, Genetics, and Pathology

Brenda M Birmann,
Brigham and Women's Hospital and Harvard Medical School, Channing Division of
Network Medicine

Brian K Link,
University of Iowa Hospitals and Clinics, Internal Medicine

Carolyn Stewart,
Memorial Sloan Kettering Cancer Center

Claire M Vajdic,
University of New South Wales, Centre for Big Data Research in Health

Corinne Haioun,
University Paris-Est Créteil (UPEC), Lymphoid Malignancies Unit, Henri Mondor
Hospital

Corrado Magnani,
Università del Piemonte Orientale, Medicina Traslazionale

David Conti,
University of Southern California, Preventive Med. Dept., Biostat.

David G Cox,
Centre de Recherche en Cancerologie de Lyon

Delphine Casabonne,
Catalan Institute of Oncology, Unit of Infections and Cancer, Cancer Epidemiology
Research Programme, IDIBELL
CIBER Epidemiología y Salud Pública

Demetrius Albanes,
National Cancer Institute, Division of Cancer Epidemiology and Genetics

Eleanor Kane,
University of York, Department of Health Sciences

Eve Roman,
University of York, Department of Health Sciences

Giacomo Muzi,
Universita degli Studi di Perugia, Department of Occupational Medicine

Gilles Salles,
Centre Hospitalier Universitaire de Lyon, Hematology

Graham G Giles,
Cancer Council Victoria, Cancer Epidemiology & Intelligence
University of Melbourne, Centre for Epidemiology and Biostatistics

Hans-Olov Adami,
Karolinska Institutet, Department of Medical Epidemiology and Biostatistics

Hervé Ghesquières,
Centre Hospitalier Universitaire de Lyon, Hematology

Immacolata De Vivo,
Brigham and Women's Hospital, Channing Division of Network Medicine
Brigham Women's Hospital and Harvard Medical School

Jacqueline Clavel,
INSERM, Department of Environmental Epidemiology of Cancers

James R Cerhan,
Mayo Clinic, Health Sciences Research and Clinical Epidemiology

John J Spinelli,
British Columbia Cancer Agency, Population Oncology

Jonathan N Hofmann,
National Cancer Institute Division of Cancer Epidemiology and Genetics

Joseph Vijai,
Memorial Sloan Kettering Cancer Center

Karen Curtin,
Huntsman Cancer Institute

Karen H Costenbader,
Brigham and Women's Hospital, Medicine, Rheumatology, Immunology and Allergy

Kenan Onel,
University of Chicago, Pediatrics

Kenneth Offit,
Memorial Sloan Kettering Cancer Center, Department of Medicine
Memorial Sloan Kettering Cancer Center, Department of Cancer Biology and
Genetics

Lauren R Teras,
American Cancer Society, Epidemiology Research Program

Lindsay M Morton,

National Cancer Institute, Division of Cancer Epidemiology and Genetics

Lucia Conde,
University College London Cancer Institute

Lucia Miligi,
Institute of Oncology Studies and Prevention

Mads Melbye,
Statens Serum Institut, Epidemiology Research

Stanford University, Medicine

Maria Grazia Ennas,
University of Caligari, Biomedical Sciences

Mark Liebow,
Mayo Clinic, Internal Medicine

Mark P Purdue,
National Cancer Institute, Division of Cancer Biology

Martha Glenn,
Huntsman Cancer Institute

Melissa C Southey,
University of Melbourne, Department of Clinical Pathology, Genetic Epidemiology
Laboratory

Monash University, Precision Medicine, School of Clinical Sciences at Monash
Health

Nathaniel Rothman,
National Cancer Institute, Division of Cancer Epidemiology and Genetics

Nicola J Camp,
Huntsman Cancer Institute

University of Utah, Internal Medicine and Biomedical Informatics

Nicole Wong Doo,
University of Sydney, Concord Hospital Clinical School

Cancer Council Australia, Centre for Epidemiology and Intelligence

Nikolaus Becker,
Deutsches Krebsforschungszentrum, Cancer Epidemiology

Nisha Pradhan,
Memorial Sloan Kettering Cancer Center

Paige M Bracci,
University of California San Francisco, Department of Epidemiology and
Biostatistics

Paolo Boffetta,

Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute

Paolo Vineis,
Imperial College London, Environmental Epidemiology and Public Health

Paul Brennan,
International Agency for Research on Cancer (IARC)

Peter Kraft,
Harvard School of Public Health, Departments of Epidemiology and Biostatistics

Qing Lan,
National Cancer Institute, Division of Cancer Epidemiology and Genetics

Richard K Severson,
Wayne State University, Karmanos Cancer Institute, Department of Family Medicine
and Public Health Sciences

Roel C H Vermeulen,
Universiteit Utrecht, Institute for Risk Assessment Science

Roger L Milne,
University of Melbourne, Centre for Epidemiology and Biostatistics

Cancer Council Australia, Epidemiology and Intelligence

Rudolph Kaaks,
German Cancer Research Center, Division of Cancer Epidemiology

Ruth C Travis,
University of Oxford, Cancer Epidemiology Unit

Stephanie Weinstein,
National Cancer Institute, NIH, Division of Cancer Epidemiology and Genetics

Stephen J Chanock,
National Cancer Research Institute, Division of Cancer Epidemiology and Genetics

Stephen M Ansell,
Mayo Clinic, Internal Medicine

Susan L Slager,
Mayo Clinic, Health Sciences Research

Tongzhang Zheng,
Brown University, School of Public Health

Yawei Zhang,
Yale University School of Public Health, Environmental Health Sciences

Yolanda Benavente,
Institut Catala d' Oncologia, Unit of Infections and Cancer, Cancer Epidemiology
Research Programme, IDIBELL, CIBER Epidemiología y Salud Pública

Lohith Madireddy,

University of California, San Francisco, Neurogenetics

Pierre-Antoine Gourraud,
Université de Nantes, Inserm, Centre de Recherche en Transplantation et
Immunologie

Centre Hospitalier Universitaire de Nantes, Institut de Transplantation Urologie
Néphrologie (ITUN)

Jorge R Oksenberg,
University of California, San Francisco, Neurogenetics

Wendy Cozen,
University of Southern California - Norris Comprehensive Cancer Center and
Hospital, Departments of Preventive Medicine and Pathology

Henrik Hjalgrim*,
Statens Serum Institut, Division of Epidemiology

Pouya Khankhanian*
Hospital of the University of Pennsylvania, Neurology

Affiliations

California Northstate University, Medicine

California Northstate University, Medicine

Hospital of the University of Pennsylvania, Neurology

Karolinska Institutet, Karolinska University Hospital, Division of Clinical
Epidemiology, Dept of Medicine

McGill University, Medicine

Research Institute, McGill University Health Centre, Clinical Epidemiology

National Cancer Institute, Division of Cancer Epidemiology and Genetics

Emory University, Medicine

University Medical Centre Freiburg, Centre of Chronic Immunodeficiency

City of Hope and the Beckman Research Institute, Department of Population
Sciences

International Agency for Research on Cancer

University of Caligari, Department of Medical Sciences and Public Health

University of Burgundy-Franche-Comté and CHU Dijon Bourgogne, Registre des
Hémopathies Malignes de Côte d'Or, INSERM U1231

Masaryk Memorial Cancer Institute, Department of Cancer Epidemiology and
Genetics

Dublin City University, Nursing and Human Science

University of Southern California, Norris Comprehensive Cancer Center and Hospital

Institut Catala d' Oncologia, L'Hospitalet de Llobregat

King's College London, Medical Education

Karolinska Institutet, Department of Medicine

University of California, Davis

California State University Sacramento

Center of Research in Epidemiology and Statistics, Sorbonne (CRESS),
Epidemiology of childhood and adolescent cancer group, INSERM

Institut Bergonie, Registre des Hémopathies Malignes de la Gironde

NYU School of Medicine, Obstetrics and Gynecology

National Cancer Institute, Division of Cancer Epidemiology and Genetics

Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency

Simon Fraser University, Department of Biomedical Physiology and Kinesiology

Mayo Clinic, Medicine

Uppsala Universitet, Department of Immunology, Genetics, and Pathology

Brigham and Women's Hospital and Harvard Medical School, Channing Division of Network Medicine

University of Iowa Hospitals and Clinics, Internal Medicine

Memorial Sloan Kettering Cancer Center

University of New South Wales, Centre for Big Data Research in Health

University Paris-Est Créteil (UPEC), Lymphoid Malignancies Unit, Henri Mondor Hospital

Università del Piemonte Orientale, Medicina Traslazionale

University of Southern California, Preventive Med. Dept., Biostat.

Centre de Recherche en Cancerologie de Lyon

Catalan Institute of Oncology, Unit of Infections and Cancer, Cancer Epidemiology Research Programme, IDIBELL

CIBER Epidemiología y Salud Pública

National Cancer Institute, Division of Cancer Epidemiology and Genetics

University of York, Department of Health Sciences

University of York, Department of Health Sciences

Università degli Studi di Perugia, Department of Occupational Medicine

Centre Hospitalier Universitaire de Lyon, Hematology
Cancer Council Victoria, Cancer Epidemiology & Intelligence
University of Melbourne, Centre for Epidemiology and Biostatistics
Karolinska Institutet, Department of Medical Epidemiology and Biostatistics
Centre Hospitalier Universitaire de Lyon, Hematology
Brigham and Women's Hospital, Channing Division of Network Medicine
Brigham Women's Hospital and Harvard Medical School
INSERM, Department of Environmental Epidemiology of Cancers
Mayo Clinic, Health Sciences Research and Clinical Epidemiology
British Columbia Cancer Agency, Population Oncology
National Cancer Institute Division of Cancer Epidemiology and Genetics
Memorial Sloan Kettering Cancer Center
Huntsman Cancer Institute
Brigham and Women's Hospital, Medicine, Rheumatology, Immunology and Allergy
University of Chicago, Pediatrics
Memorial Sloan Kettering Cancer Center, Department of Medicine
Memorial Sloan Kettering Cancer Center, Department of Cancer Biology and Genetics
American Cancer Society, Epidemiology Research Program
National Cancer Institute, Division of Cancer Epidemiology and Genetics
University College London Cancer Institute
Institute of Oncology Studies and Prevention
Statens Serum Institut, Epidemiology Research
Stanford University, Medicine
University of Caligari, Biomedical Sciences
Mayo Clinic, Internal Medicine
National Cancer Institute, Division of Cancer Biology
Huntsman Cancer Institute
University of Melbourne, Department of Clinical Pathology, Genetic Epidemiology Laboratory
Monash University, Precision Medicine, School of Clinical Sciences at Monash Health
National Cancer Institute, Division of Cancer Epidemiology and Genetics

Huntsman Cancer Institute
University of Utah, Internal Medicine and Biomedical Informatics
University of Sydney, Concord Hospital Clinical School
Cancer Council Australia, Centre for Epidemiology and Intelligence
Deutsches Krebsforschungszentrum, Cancer Epidemiology
Memorial Sloan Kettering Cancer Center
University of California San Francisco, Department of Epidemiology and Biostatistics
Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute
Imperial College London, Environmental Epidemiology and Public Health
International Agency for Research on Cancer (IARC)
Harvard School of Public Health, Departments of Epidemiology and Biostatistics
National Cancer Institute, Division of Cancer Epidemiology and Genetics
Wayne State University, Karmanos Cancer Institute, Department of Family Medicine and Public Health Sciences
Universiteit Utrecht, Institute for Risk Assessment Science
University of Melbourne, Centre for Epidemiology and Biostatistics
Cancer Council Australia, Epidemiology and Intelligence
German Cancer Research Center, Division of Cancer Epidemiology
University of Oxford, Cancer Epidemiology Unit
National Cancer Institute, NIH, Division of Cancer Epidemiology and Genetics
National Cancer Research Institute, Division of Cancer Epidemiology and Genetics
Mayo Clinic, Internal Medicine
Mayo Clinic, Health Sciences Research
Brown University, School of Public Health
Yale University School of Public Health, Environmental Health Sciences
Institut Catala d' Oncologia, Unit of Infections and Cancer, Cancer Epidemiology Research Programme, IDIBELL, CIBER Epidemiología y Salud Pública
University of California, San Francisco, Neurogenetics
Université de Nantes, Inserm, Centre de Recherche en Transplantation et Immunologie
Centre Hospitalier Universitaire de Nantes, Institut de Transplantation Urologie Néphrologie (ITUN)

University of California, San Francisco, Neurogenetics

University of Southern California - Norris Comprehensive Cancer Center and
Hospital, Departments of Preventive Medicine and Pathology

Statens Serum Institut, Division of Epidemiology

Hospital of the University of Pennsylvania, Neurology

ACKNOWLEDGEMENTS

Support for authors

All 92 authors agree that there are no conflicts of interest to report.

Hans-Olov Adami is supported by the Karolinska Institutet Distinguished Professor Award (Dnr: 2368/10-221).

Nicola Camp reports support from NIH R01CA134674. Partial support for data collection at the Utah site was made possible by the Utah Population Database (UPDB) and the Utah Cancer Registry (UCR). Partial support for all datasets within the UPDB is provided by the Huntsman Cancer Institute (HCI) and the HCI Comprehensive Cancer Center Support grant, P30 CA42014. The UCR is supported in part by NIH contract HHSN261201000026C from the National Cancer Institute SEER Program with additional support from the Utah State Department of Health and the University of Utah.

James R Cerhan is supported by NIH grants R01 CA92153, R01 CA200703, P50 CA97274, U01 CA195568, and the Henry J Predolin Foundation.

David Conti is funded by the following grants: P01CA196569, R01CA201407, R01CA140561, ES024844, and R01ES016813.

Lenka Foretova is supported by a grant MH CZ - DRO (MMCI, 00209805).

Pierre-Antoine Gourraud is supported by the ATIP-Avenir INSERM program and the Region Pays de Loire ConnecTalent, ARSEP Foundation (France) and the Nantes University Foundation.

Karin E Smedby is supported by the Swedish Cancer Society (2009/659, 02 6661), the Strategic Research Program in Epidemiology at Karolinska Institute and National Institutes of Health (5R01 CA69669-02).

John J Spinelli is supported by the Canadian Institutes for Health Research (CIHR); the Canadian Cancer Society; and the Michael Smith Foundation for Health Research

Support for Studies

ATBC – Intramural Research Program of the National Institutes of Health, NCI, Division of Cancer Epidemiology and Genetics. U.S. Public Health Service contracts (N01-CN- 45165, N01-RC-45035, N01-RC-37004, HHSN261201000006C).

BC (J.S., A.B.W.) – Canadian Institutes for Health Research (CIHR). Canadian Cancer Society. Michael Smith Foundation for Health Research.

CLL Meta-Analysis: We thank I. Brock, K. Butterbach, A. Chabrier, D. Chan-Lam, D. Connley, H. Cramp, R. Cutting, C. Dalley, H. Dykes, A. Gabbas, P. Gaddam, P. Hui, L. Irish, L. Jacobus, S. Kaul, L. Klareskog, A. Lai, J. Lunde, M. McAdams, L. Padyukov, D. Parisi, V. Rajamanickam, T. Rattle, L. Rigacci, R. Sargent, G. Specchia, M. Stagner, P. Taylor, C. Tornow, J. Williams and G. Wood. The overall GWAS project was supported by the intramural programme of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institutes of Health.

CPSII (L.T.) – The American Cancer Society funds the creation, maintenance, and updating of the CPSII cohort. The authors thank the CPS-II participants and Study Management Group for their invaluable contributions to this research. The authors would also like to acknowledge the contribution to this study from central cancer registries supported through the Centers for Disease Control and Prevention National Program of Cancer Registries, and cancer registries supported by the National Cancer Institute Surveillance Epidemiology and End Results program.

EIRA - The authors acknowledge the help of Peter K Gregersen and Jane Worthington in access to NARAC and WTCCC data. They also thank Robert M Plenge for careful reading of the manuscript and critical discussions; Kian Mun Chan, Boon Yeong Goh, Wee Yang Meah, Jameelah B S Mohamed, Jason Ong, Eileen Ping and Sigeeta Rajaram for their invaluable laboratory assistance; the participating patients with RA and controls and all rheumatologists for recruiting patients in the EIRA study; and Marie-Louise Serra, Camilla Bengtsson, Eva Jemseby and Lena Nise for their invaluable contributions to the collection of data and maintenance of the database.

ELCCS (E.R.) - The ECSG Lymphoma Case-Control Study (ELCCS) were funded by Bloodwise and Leukaemia & Lymphoma Research.

ENGELA (J.C.) – Fondation ARC pour la Recherche sur le Cancer. Fondation de France. French Agency for Food, Environmental and Occupational Health & Safety (ANSES), the French National Cancer Institute (INCa).

EPIC (E.R.) – Coordinated Action (Contract #006438, SP23-CT-2005-006438). HuGeF (Human Genetics Foundation), Torino, Italy.

EPILYMPH – European Commission (grant references QLK4-CT-2000-00422 and FOOD-CT-2006-023103); the Spanish Ministry of Health (grant references CIBERESP, P111/01810, RCESP C03/09, RTICESP C03/10 and RTIC RD06/0020/0095), the Marató de TV3 Foundation (grant reference 051210), the Agència de Gestió d'Ajuts Universitaris de Recerca – Generalitat de Catalunya (grant references 2014SRG756 and 2009SGR1465) who had no role in the data collection, analysis or interpretation of the results; the NIH (contract NOI-CO-12400); the Compagnia di San Paolo—Programma Oncologia; the Federal Office for Radiation Protection grants StSch4261 and StSch4420, the José Carreras Leukemia Foundation grant DJCLS-R12/23, the German Federal Ministry for Education and Research (BMBF-01-EO-1303); the Health Research Board, Ireland and Cancer Research Ireland; Czech Republic supported by MH CZ – DRO (MMCI, 00209805) and RECAMO, CZ. 1.05/2.1.00/03.0101; Fondation de France and Association de Recherche Contre le Cancer.

GEC/Mayo GWAS - National Institutes of Health (CA118444, CA148690, CA92153). Intramural Research Program of the NIH, National Cancer Institute. Veterans Affairs Research Service. Data collection for Duke University was supported by a Leukemia & Lymphoma Society Career Development Award, the Bernstein Family Fund for Leukemia and Lymphoma Research, and the National Institutes of Health (K08CA134919), National Center for Advancing Translational Science (UL1 TR000135).

GELA (G.S.) – The French National Cancer Institute (INCa).

HPFS (Walter C. Willet) – The HPFS was supported in part by National Institutes of Health grants CA167552, CA149445 and CA098122. We would like to thank the participants and staff of the Health Professionals Follow-up Study for their valuable contributions as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. The authors assume full responsibility for analyses and interpretation of these data.

IMSGC-WTCCC2 The principal funding for this study was provided by the Wellcome Trust (085475/B/08/Z, 085475/Z/08/Z, 075491/Z/04/Z and 068545/Z/02). The work was also supported by National Institutes of Health (AI076544, NS032830, NS049477, NS19142, NS049510, NS26799, NS43559, NS067305, CA104021, RR020092, RR024992 and K23N/S048869), US National Multiple Sclerosis Society (RG 4201-A-1), Nancy Davis Foundation, Cambridge NIHR Biomedical Research Centre, UK Medical Research Council (G0700061, G0000934), Multiple Sclerosis Society of Great Britain and Northern Ireland (898/08), Wolfson Royal Society Merit Award, Peter Doherty fellowship, Lagrange Fellowship, Harry Weaver Neuroscience Scholarships, Australian National Health and Medical Research Council (NHMRC), Australian Research Council Linkage Program Grant, JHH Charitable Trust Fund, Multiple Sclerosis Research Australia, Health Research Council New Zealand, National MS Society of New Zealand, Wetenschappelijk Onderzoek Multiple Sclerose, Bayer Chair on Fundamental Genetic Research regarding the Neuroimmunological Aspects of Multiple Sclerosis, Biogen Idec Chair Translational Research in Multiple Sclerosis, FWO-Vlaanderen, Belgian Neurological Society, Danish Multiple Sclerosis Society, Neuropromise EU grant (LSHM-CT-2005-018637), Center of Excellence for Disease Genetics of the Academy of Finland, Sigrid Juselius Foundation, Helsinki University Central Hospital Research Foundation, Bundesministerium für Bildung und Technologie (KKNMS consortium Control MS), Deutsche Forschungsgemeinschaft, Institut National de la Santé et de la Recherche Médicale (INSERM), Association pour la Recherche sur la Sclérose En Plaques (ARSEP), Association Française contre les Myopathies (AFM), Italian Foundation for Multiple Sclerosis (FISM grants 2002/R/40, 2005/R/10, 2008/R/11 and 2008/R/15), Italian Ministry of Health (grant Giovani Ricercatori 2007 - D.lgs 502/92), Regione Piemonte (grants 2003, 2004, 2008, 2009), CRT Foundation, Turin, Moorfields/UCL Institute of Ophthalmology NIHR Biomedical Research Centre, Norwegian MS Register and Biobank, Research Council of Norway, South-Eastern and Western Norway regional Health Authorities, Ullevål University Hospital Scientific Advisory Council, Haukeland University Hospital, Amici Centro Sclerosi Multipla del San Raffaele (ACESM), Association of British Neurologists, Spanish Ministry of Health (FISPI060117), Bibbi and Niels Jensens Foundation, Montel Williams foundation, Hjärfonden and Swedish medical research council

(8691), Stockholm County Council (562183), Swedish Council for Working life and Social Research, Gemeinnützige Hertie Stiftung, Northern California Kaiser Permanente members and Polpharma Foundation, and Washington University Institute of Clinical and Translational Sciences—Brain, Behavioral and Performance Unit. We acknowledge use of data from the British 1958 Birth Cohort, the UK National Blood Service, the popgen biobank, the KORA and MONICA Augsburg studies, the Accelerated Cure Project, the Brigham & Women's Hospital PhenoGenetic Project, the Swedish CAD project, the Norwegian Bone Marrow Donor Registry, the Children's Hospital of Philadelphia (CHOP), the Swedish Breast Cancer study, BRC-REFGENSEP (Pitié-Salpêtrière Centre d'Investigation Clinique (CIC) and Génomique) and HYPERGENES (HEALTH-F4-2007-201550). Projects received support from the German Ministry of Education and Research, the Helmholtz Zentrum München—National Research Center, the German National Genome Research Network (NGFN), the LMUinnovativ, the Knut and Alice Wallenberg Foundation, the Center for Applied Genomics from the Children's Hospital of Philadelphia Development Award, the Agency for Science & Technology and Research of Singapore, and the Susan G. Komen Breast Cancer Foundation.

Iowa-Mayo SPORE (G.W., J.R.C., T.E.W.) – National Institutes of Health (CA97274). NCI Specialized Programs of Research Excellence (SPORE) in Human Cancer (P50 CA97274). Molecular Epidemiology of Non-Hodgkin Lymphoma Survival (R01 CA129539), National Cancer Institute (P30 CA086862, P30 CA15083). Henry J. Predolin Foundation.

Italian GxE (P.C.) - Italian Ministry for Education, University and Research (PRIN 2007 prot. 2007WEJLZB, PRIN 2009 prot. 2009ZELR2); the Italian Association for Cancer Research (AIRC, Investigator Grant 11855). (M.G.E.) - Regional Law N. 7, 2007: "Basic research" (Progetti di ricerca fondamentale o di base) by the Regional Administration of Sardinia (LR7 CRP-59812/2012), Fondazione Banco di Sardegna 2010–2012.

LYSA (G.S, H.G) – Institut National du Cancer (INCa, Paris) grant 2008-020

Mayo Clinic Case-Control (J.R.C.) – National Institutes of Health (R01 CA92153). National Center for Advancing Translational Science (UL1 TR000135). National Cancer Institute (P30 CA015083).

MCCS (G.G.G., G.S.) –The Melbourne Collaborative Cohort Study (MCCS) cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further supported by Australian National Health and Medical Research Council grants 209057, 251553, 504711, 396414 and by infrastructure provided by Cancer Council Victoria. Cases and their vital status were ascertained through the Victorian Cancer Registry and the Australian Institute of Health and Welfare, including the National Death Index and the Australian Cancer Database. The MCCS was made possible by the contribution of many people, including the original investigators, the teams that recruited the participants and continue working on follow-up, and the many thousands of Melbourne residents who continue to participate in the study.

MCC-Spain - The MCC-Spain study is funded by The Instituto de Salud Carlos III (ISCIII – Spanish Government) (PI11/01810, PI14/01219, RCESP C03/09, and CIBERESP); the Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR) – Generalitat de Catalunya (Catalonian Government) (2014SGR756). Nadia García and Marleny Vergara (ICO-IDIBELL) provided technical support for this study.

MD Anderson (X.W.) – Institutional support to the Center for Translational and Public Health Genomics.

MSKCC (K.O.) – Geoffrey Beene Cancer Research Grant, Lymphoma Foundation (LF5541). Barbara K. Lipman Lymphoma Research Fund (74419). Robert and Kate Niehaus Clinical Cancer Genetics Research Initiative (57470), U01 HG007033. ENCODE, U01 HG007033 (J.V.).

NCI-SEER – Intramural Research Program of the National Cancer Institute, National Institutes of Health, and Public Health Service (N01-PC-65064, N01-PC-67008, N01-PC-67009, N01-PC-67010, N02-PC-71105).

NHS (Meir J. Stampfer) – The NHS was supported in part by National Institutes of Health grants CA186107, CA87969, CA49449, CA149445, CA098122 and CA134958. We would like to thank the participants and staff of the Nurses' Health Study for their valuable contributions as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. The authors assume full responsibility for analyses and interpretation of these data.

NSW NHL Study (C.M.Vajdic) - was supported by grants from the Australian National Health and Medical Research Council (ID990920), the Cancer Council NSW, and the University of Sydney Faculty of Medicine.

NSFC - the National Natural Science Foundation of China (No. 61471078).

NYUWHS - National Cancer Institute (R01 CA098661, P30 CA016087). National Institute of Environmental Health Sciences (ES000260).

PLCO - This research was supported by the Intramural Research Program of the National Cancer Institute and by contracts from the Division of Cancer Prevention, National Cancer Institute, NIH, DHHS.

SLE- The Health and Retirement Study genetic data were obtained from dbGaP under accession phs000187.v1; the study is sponsored by the National Institute on Aging (grant numbers U01AG009740, RC2AG036495, and RC4AG039029) and was conducted by the University of Michigan. The melanoma study data were obtained from dbGaP under accession number phs000187.v1.p1. Research support to collect data and develop an application to support this project was provided by 3P50CA093459, 5P50CA097007, 5R01ES011740, and 5R01CA133996. Funding support for the Genes and Blood Clotting Study was provided through the NIH/NHLBI (R37HL039693). The Genes and Blood Clotting Study is one of the Phase 3 studies as part of the Gene Environment Association Studies (GENEVA) under GEI. Assistance with genotype cleaning was provided by the GENEVA Coordinating Center (U01 HG004446). Funding support for DNA extraction and genotyping, which was performed at the Broad Institute, was provided by NIH/NHLBI (R37HL039693). Additional support was provided by the Howard Hughes Medical Institute. The datasets used for the analyses described in this manuscript were obtained from dbGaP at <http://www.ncbi.nlm.nih.gov/sites/entrez?db=gap> through dbGaP accession number phs000304.v1.p1. The CGEMS prostate cancer study data were obtained from dbGaP under accession phs000207v1

SCALE (K.E.S., H.O.A., H.H.) – Swedish Cancer Society (2009/659). Stockholm County Council (20110209) and the Strategic Research Program in Epidemiology at Karolinska Institute. Swedish Cancer Society grant (02 6661). Danish Cancer Research Foundation Grant. Lundbeck Foundation Grant (R19-A2364). Danish Cancer Society Grant (DP 08-155). National Institutes of Health (5R01 CA69669-02). Plan Denmark.

UCSF/UCSF2 (E.A.H., P.M.B, C.F.S.) – The UCSF studies were supported by the NCI, National Institutes of Health, CA87014, CA1046282, CA122663 and CA154643, and R01CA87014, R01CA45614, R03CA14397, and R03CA150037 (E.A.H., P.M.B). The collection of cancer incidence data used in this study was supported by the California Department of Health Services as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; the National Cancer Institute’s Surveillance, Epidemiology, and End Results Program under contract HHSN261201000140C awarded to the Cancer Prevention Institute of California, contract HHSN261201000035C awarded to the University of Southern California, and contract HHSN261201000034C awarded to the Public Health Institute; and the Centers for Disease Control and Prevention’s National Program of Cancer Registries, under agreement #1U58 DP000807-01 awarded to the Public Health Institute. The ideas and opinions expressed herein are those of the authors, and endorsement by the State of California, the California Department of Health Services, the National Cancer Institute, or the Centers for Disease Control and Prevention or their contractors and subcontractors is not intended nor should be inferred.

UTAH/Sheffield - National Institutes of Health CA134674. Partial support for data collection at the Utah site was made possible by the Utah Population Database (UPDB) and the Utah Cancer Registry (UCR). Partial support for all datasets within the UPDB is provided by the Huntsman Cancer Institute (HCI) and the HCI Cancer Center Support grant, P30 CA42014. The UCR is supported in part by NIH contract HHSN261201000026C from the National Cancer Institute SEER Program with additional support from the Utah State Department of Health and the University of Utah. Partial support for data collection in Sheffield, UK was made possible by funds from Yorkshire Cancer Research and the Sheffield Experimental Cancer Medicine Centre. We thank the NCRI Haemato-oncology Clinical Studies Group, colleagues in the North Trent Cancer Network the North Trent Haemato-oncology Database.

WHI - WHI investigators are: Program Office - (National Heart, Lung, and Blood Institute, Bethesda, Maryland) Jacques Rossouw, Shari Ludlam, Dale Burwen, Joan McGowan, Leslie Ford, and Nancy Geller; Clinical Coordinating Center - (Fred Hutchinson Cancer Research Center, Seattle, WA) Garnet Anderson, Ross Prentice, Andrea LaCroix, and Charles Kooperberg; Investigators and Academic Centers - (Brigham and Women’s Hospital, Harvard Medical School, Boston, MA) JoAnn E. Manson; (MedStar Health Research Institute/Howard University, Washington, DC) Barbara V. Howard; (Stanford Prevention Research Center, Stanford, CA) Marcia L. Stefanick; (The Ohio State University, Columbus, OH) Rebecca Jackson; (University of Arizona, Tucson/Phoenix, AZ) Cynthia A. Thomson; (University at Buffalo, Buffalo, NY) Jean Wactawski-Wende; (University of Florida, Gainesville/Jacksonville, FL) Marian Limacher; (University of Iowa, Iowa City/Davenport, IA) Robert Wallace; (University of Pittsburgh, Pittsburgh, PA) Lewis Kuller; (Wake Forest University School of Medicine, Winston-Salem, NC) Sally Shumaker; Women’s Health Initiative Memory Study - (Wake Forest University School of Medicine, Winston-Salem, NC) Sally Shumaker. The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C.

WTCCC1 - The principal funder of this project was the Wellcome Trust. Case collections were funded by: Arthritis Research Campaign, BDA Research, British Heart Foundation, British Hypertension Society, Diabetes UK, Glaxo-Smith Kline Research and Development, Juvenile Diabetes Research Foundation, National Association for Colitis and Crohn’s disease, SHERT (The Scottish Hospitals Endowment Research Trust), St Bartholomew’s and The Royal London Charitable Foundation, UK Medical Research Council, UK NHS R&D and the Wellcome Trust.

Statistical analyses were funded by a Commonwealth Scholarship, EU, EPSRC, Fundação para a Ciência e a Tecnologia (Portugal), National Institutes of Health, National Science Foundation and the Wellcome Trust. We acknowledge the many physicians, research fellows and research nurses who contributed to the various case collections, and the collection teams and senior management of the UK Blood Services responsible for the UK Blood Services Collection. For the 1958 Birth Cohort, venous blood collection was funded by the UK Medical Research Council and cell-line production, DNA extraction and processing by the Juvenile Diabetes Research Foundation and the Wellcome Trust.

YALE (T.Z.) – National Cancer Institute (CA62006).

References

- Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, ... Klareskog L (2006). Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. *Arthritis and Rheumatism*
- Baecklund E, Smedby K, Sutton L, Askling J, & Rosenquist R (2014). Lymphoma development in patients with autoimmune and inflammatory disorders - What are the driving forces? *Seminars in Cancer Biology*, 24, 61–70. [PubMed: 24333759]
- Belbasis L, Bellou V, Evangelou E, Ioannidis J, & Tzoulaki I (2015). Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses. *Lancet Neurol*, 14, 263–273. [PubMed: 25662901]
- Bentham J, Morris D, Cunninghame Graham D, Pinder C, Tomblason P, Behrens T, ... Vyse T (2015). Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus. *Nature Genetics*, 47, 1457–1464. [PubMed: 26502338]
- Bernatsky S, Ramsey-Goldman R, Labrecque J, Joseph L, Boivin JF, Petri M, ... Clarke AE (2013, 5). Cancer risk in systemic lupus: An updated international multi-centre cohort study. *Journal of Autoimmunity*, 42, 130–135. [PubMed: 23410586]
- Bernatsky S, Velásquez García HA, Spinelli JJ, Gaffney P, Smedby KE, Ramsey-Goldman R, ... Angelucci E (2017, 11). Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma. *Lupus Sci Med*, 4(1), 187.
- Berndt S, Camp N, Skibola C, Vijai J, Wang Z, Gu J, ... Slager S (2016). Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. *Nat Commun*, 7, 1–9.
- Cerhan J, Berndt S, Vijai J, Ghesquières H, McKay J, Wang S, ... Chanock S (2014). Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. *Nature Genetics*, 46, 1233–8. [PubMed: 25261932]
- Daniel Himmelstein; Pouya Khankhanian; Sergio Baranzini. (2015). A human disease network from GWAS loci Zenodo.
- Deane K, O'Donnell C, Hueber W, Majka D, Lazar A, Derber L, ... Holers V (2010). The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner. *Arthritis and Rheumatism*, 62, 3161–3172. [PubMed: 20597112]
- Ekström K, Hjalgrim H, Brandt L, Baecklund E, Klareskog L, Ekbom A, & Askling J (2003). Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. *Arthritis and Rheumatism*, 48, 963–970. [PubMed: 12687538]
- Hemminki K, Försti A, Sundquist K, Sundquist J, & Li X (2017, 1). Familial associations of lymphoma and myeloma with autoimmune diseases. *Blood Cancer Journal*, 7, e515. [PubMed: 28157190]
- International Multiple Sclerosis Genetics Consortium, T. (2011). Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. *Nature*, 476, 214–9. [PubMed: 21833088]
- Khankhanian P, Cozen W, Himmelstein D, Madireddy L, Din L, Van Den Berg A, ... Hjalgrim H (2016). Meta-analysis of genome-wide association studies reveals genetic overlap between Hodgkin lymphoma and multiple sclerosis. *International Journal of Epidemiology*, 45, 728–740. [PubMed: 26971321]

- Padyukov L, Seielstad M, Ong RT, Ding B, Rönnelid J, Seddighzadeh M, ... group, E. S. (2011, 2). A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis. *Annals of the Rheumatic Diseases*, 70(2), 259–265. [PubMed: 21156761]
- Park Y-W, Kee S-J, Cho Y-N, Lee E-H, Lee H-Y, Kim E-M, ... Kang H-S (2009). Impaired differentiation and cytotoxicity of natural killer cells in systemic lupus erythematosus. *Arthritis and rheumatism*, 60, 1753–1763. [PubMed: 19479851]
- Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira M, Bender D, ... Sham P (2007). PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage Analyses. *The American Journal of Human Genetics*, 81, 559–575. [PubMed: 17701901]
- R Core Team, R. (2013). R: A language and environment for statistical computing R Foundation for Statistical Computing Vienna, Austria.
- Skibola C, Berndt S, Vijai J, Conde L, Wang Z, Yeager M, ... Rothman N (2014). Genome-wide association study identifies five susceptibility loci for follicular lymphoma outside the HLA region. *American Journal of Human Genetics*, 95, 462–71. [PubMed: 25279986]
- Smedby K, & Ponzoni M (2017). The aetiology of B-cell lymphoid malignancies with a focus on chronic inflammation and infections. *Journal of Internal Medicine*, 282, 360–370. [PubMed: 28875507]
- Thun M, Linet M, Cerhan J, Haiman C, & Schottenfeld D (2017). *Schottenfeld and Fraumeni Cancer Epidemiology and Prevention (Fourth Edition ed.)*. Oxford University Press.
- Vijai J, Wang Z, Berndt S, Skibola C, Slager S, Bracci P, ... Nieters A (2015). A genome-wide association study of marginal zone lymphoma shows association to the HLA region. *Nature Communications*, 6, 5751.
- Wellcome Trust Case Control Consortium, T. (2007, 6). Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature*, 447(7145), 661–678. [PubMed: 17554300]

KEY MESSAGES

Within the limits of this GWAS-based cross-disease analysis, the shared genetic risk between SLE, RA, MS, and four common B-cell NHL types was limited to few weakly associated loci and explained little total disease risk.

Candidate genes with roles in the cell cycle, apoptosis, and telomere length should be considered in future analyses of shared genetic susceptibility to these conditions.

Further meta-analyses of genetic variants in autoimmune diseases and lymphomas with larger datasets and deeper sequencing may provide further insight into mechanisms common to the two groups of diseases.

Overlapping SNPs	MS	SLE	RA
	465,434 SNPs	623,954 SNPs	603,325 SNPs
CLL 9,116,853 SNPs	460,908 SNPs	609,999 SNPs	594,537 SNPs
DLBCL 9,116,853 SNPs	460,981 SNPs	610,319 SNPs	594,517 SNPs
FLL 9,078,855 SNPs	461,003 SNPs	610,241 SNPs	594,551 SNPs
MZL 8,478,065 SNPs	459,792 SNPs	605,797 SNPs	593,751 SNPs





Figure 1.

Study design and data analysis procedures. For each of the 12 pairs of diseases (three ADs and four NHLs), results from previous GWAS were used to assess genetic overlap between the two diseases. SNPs independently associated with both diseases were identified. Genetic risk scores were evaluated for genomewide overlap. Network analysis evaluated the proximity of these diseases in the context of other human diseases. After the evaluation of genetic overlap, we merged GWAS results for each AD-NHL in a meta-analysis to discover novel genes associated with both diseases. (AD = Autoimmune disease; NHL = Non-Hodgkin Lymphoma).



Proximity between diseases




Figure 2:
 Panel 1. A graph of autoimmune diseases (purple), solid cancers (orange), hematologic cancers (white), and other diseases (gray). Thickness of lines indicates greater levels of genetic overlap (proximity between diseases). Panel 2. The proximity between NHLs and ADs (blue) is greater than the proximity between NHLs and solid cancers (orange), which is greater than the proximity between NHLs and other diseases (green).

Table 1.

The GWAS used for the meta-analysis.

Disease	Study	Unique Cases	Unique Controls	Original Genotyped SNPs
MS	WTCCC2 (12)	9,772	17,376	465,434
RA	WTCCC1 (13) and EIRA (14)	3,921	4,079	650,312
SLE	Bentham study (15)	7,219	15,991	623,954
DLBCL	Groupe d'Etude des Lymphomes de l'Adulte (16)	549	525	513,264
DLBCL	Mayo-DLBCL (16)	393	172	516,286
DLBCL	San Francisco (16)	254	749	290,454
DLBCL	Omni	2,421	5,991	607,957
CLL	San Francisco	213	See SF above	290,454
CLL	Omni	1,953	See Omni above	607,957
CLL	Utah	326	413	559,899
FL	San Francisco (SF)	210	See SF above	290,454
FL	San Francisco (SF2)	119	349	599,547
FL	Scandinavian lymphoma etiology (SCALE)	376	791	297,989
FL	Omni (22 sites)	1,981	See Omni above	607,957
MZL	Omni (22 sites)	741	See Omni above	607,957

Table 2.

Overlap of SNPs between the three autoimmune diseases and the four non-Hodgkin lymphoma subtypes. See supplementary table for details of each region.

Analysis	Number of SNPs that were significant at the threshold of 5e-04	Number of SNPs with LD info available in SNAP	Number of Regions based on LD	Number of SNPs that were significant after correction (BH < 0.05)
SLE SNPs in DLBCL	2472	1718	389	2
DLBCL SNPs in SLE	524	334	190	3
SLE SNPs in CLL	2471	1718	389	5
CLL SNPs in SLE	895	625	240	4
SLE SNPs in FL	2473	1718	389	2
FL SNPs in SLE	558	393	206	5
SLE SNPs in MZL	2462	1718	389	4
MZL SNPs in SLE	390	259	168	6
RA SNPs in DLBCL	532	423	238	0
DLBCL SNPs in RA	504	425	190	1
RA SNPs in CLL	531	423	238	1
CLL SNPs in RA	844	724	232	1
RA SNPs in FL	532	423	238	3
FL SNPs in RA	471	395	199	4
RA SNPs in MZL	530	422	237	1
MZL SNPs in RA	351	283	148	2
MS SNPs in DLBCL	1203	1031	380	6
DLBCL SNPs in MS	366	329	195	6
MS SNPs in CLL	1204	1031	380	13
CLL SNPs in MS	659	586	244	14
MS SNPs in FL	1203	1031	380	11
FL SNPs in MS	402	369	203	12
MS SNPs in MZL	1203	1031	380	0
MZL SNPs in MS	253	219	152	1

Table 3.

SNPs which were significant in a meta-analysis of an autoimmune disease with a non-Hodgkin Lymphoma, but which did not meet the threshold of significance in the autoimmune disease alone nor in the non-Hodgkin Lymphoma alone. RA = Risk allele. RDS = Regulome DB Score. Corr=Corrected for multiple hypothesis testing in a single meta-analysis. Paper corr= corrected for multiple hypothesis testing in 12 meta-analyses presented in this paper.

Study	SNP	P (AD)	OR (AD)	p (NHL)	OR (NHL)	p (Meta)	Corr. p (Meta)	Paper corr. p (Meta)	OR (Meta)	Chr	Gene(s) of interest	RA	RDS
CLL vs. MS	rs140522	3.85E-06	0.91	1.18E-05	0.86	6.49E-11	2.99E-05	4.32E-04	0.90	22	ODF3B	A	4
CLL vs. MS	rs6793295	1.48E-05	0.91	1.10E-04	0.87	1.86E-09	8.59E-04	1.24E-02	0.90	3	LRRC34	A	7
CLL vs. RA	rs3731714	1.33E-03	0.89	7.82E-07	0.84	7.05E-09	4.19E-03	4.69E-02	0.87	2	CASP10, PPIL3, CFLAR	G	1d
DLBCL vs. MS	rs2425752	1.70E-06	0.91	1.10E-02	0.92	5.10E-09	2.35E-03	3.39E-02	0.91	20	NCOA5	A	1d
MZL vs. RA	rs16947122	3.56E-02	1.57	4.99E-03	0.51	5.03E-09	2.99E-03	3.35E-02	1.86	12	FBXW8, HRK, TESC	C	5
MZL vs. RA	rs1364229	1.73E-04	1.30	1.66E-04	0.72	1.66E-10	9.86E-05	1.10E-03	1.35	16	CDH8	A	7
MZL vs. RA	rs7192064	9.63E-04	0.79	3.67E-04	0.74	6.55E-09	3.89E-03	4.36E-02	0.76	16	CDH8	G	
MZL vs. RA	rs2131402	2.50E-04	0.77	3.67E-04	0.74	1.51E-09	8.97E-04	1.01E-02	0.75	16	CDH8	G	6
CLL vs. SLE	rs1439112	1.80E-07	0.85	3.84E-03	1.10	7.09E-09	4.33E-03	4.72E-02	0.88	2	MGAT5	A	4
CLL vs. SLE	rs10936599	1.99E-05	0.87	5.01E-05	0.86	4.06E-09	2.48E-03	2.70E-02	0.87	3	MYNN, ACTRT3, TERC, LRRC34	C	5
CLL vs. SLE	rs1317082	1.50E-05	0.86	3.73E-05	0.86	2.25E-09	1.37E-03	1.50E-02	0.86	3	MYNN, ACTRT3, TERC, LRRC34	A	6
CLL vs. SLE	rs13069553	9.55E-06	0.86	4.16E-05	0.86	1.61E-09	9.83E-04	1.07E-02	0.86	3	MYNN, ACTRT3, TERC, LRRC34	A	5
CLL vs. SLE	rs7621631	1.36E-05	0.86	4.92E-05	0.86	2.69E-09	1.64E-03	1.79E-02	0.86	3	MYNN, ACTRT3, TERC, LRRC34	C	7
CLL vs. SLE	rs10069690	7.21E-04	1.12	5.56E-07	1.21	4.60E-09	2.81E-03	3.06E-02	1.16	5	TERT	T	5

Table 4.

Classification of immune and neoplastic diseases from the diseasome.

Autoimmune diseases	Hematologic cancers
Alopecia areata (AR)	Chronic lymphocytic Leukemia (CLL)
Ankylosing spondylitis (AS)	Hodgkin lymphoma (HL)
Behcet's disease (Beh)	Mutiple myeloma (MM)
Coeliac disease (Cel)	Diffuse large B-cell lymphoma (DLBCL)
Crohn's Disease (CD)	Follicular lymphoma (FL)
Graves' Disease (GD)	Marginal zone lymphoma (MZL)
IgA glomerulonephritis (IgA)	
Kawasaki disease (Kaw)	Solid cancers
Multiple Sclerosis (MS)	Basal cell carcinoma (BCC)
Primary biliary cirrhosis (PBC)	Bladder carcinoma (BIC)
Psoriasis (Ps)	Breast carcinoma (BrC)
Psoriatic arthritis (PsA)	Central nervous system cancer (CNS)
Rheumatoid arthritis (RA)	Esophageal carcinoma (EsC)
Sclerosing cholangitis (PSC)	Lung Carcinoma (LuC)
Systemic lupus erythematosus (SLE)	Lung adenocarcinoma (LuA)
Systemic scleroderma (SS)	Melanoma (Mel)
Type 1 diabetes mellitus (T1D)	Neuroblastoma (NB)
Ulcerative colitis (UC)	Ovarian carcinoma (OvC)
Vitiligo (Vit)	Pancreatic carcinoma (PaC)
	Prostate carcinoma (PrC)
	Renal cell carcinoma (RCC)
	Squamous cell carcinoma (SCC)
	Stomach carcinoma (StC)
	Thyoid carcinoma (ThC)